Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMO | Q99835 | 4/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514660 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1L3MBTL1SMOCNR2 | |
| SCHEMBL3051541 | 0.98 | CNR2 (0.54) | KDM4EALDH1A1L3MBTL1SMOCNR2 | |
| SCHEMBL14844043 | 0.96 | SMO (0.56) | KDM4EALDH1A1L3MBTL1SMOCNR2 | |
| SCHEMBL2003952 | 0.87 | KDR (0.50) | KDM4EALDH1A1L3MBTL1SMOGPR119 | |
| SCHEMBL3550354 | 0.87 | SMO (0.47) | KDM4EALDH1A1L3MBTL1SMOCNR2 | |
| Hydrochloric Acid SCHEMBL31465050 | 0.86 | KDR (0.49) | KDM4EALDH1A1L3MBTL1SMOGPR119 | |
| SCHEMBL30390836 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1SMOGPR119 | |
| SCHEMBL2349007 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1SMOGPR119 | |
| SCHEMBL231983 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1SMOGPR119 | |
| SCHEMBL23073696 | 0.85 | SMO (0.46) | KDM4EALDH1A1L3MBTL1SMOGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115605477-B | Pyrazolo [1,5-a ] pyridine derivative, preparation method, composition and application thereof | 深圳众格生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-114181205-B | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024029489-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MODULUS DISCOVERY, INC. (JP) | 2024-02-08 | — | — | WO | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-115605477-A | Pyrazolo [1,5-a ] pyridine derivative and preparation method, composition and application thereof | 深圳众格生物科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023275744-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022053046-A1 | PYRAZOLOPYRIDINE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| CN-114181205-A | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2021213476-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 深圳晶泰科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6462047-B1 | CONTAINING 5- OR 6-MEMBERED OXYGEN, NITROGEN AND/OR SULFUR HETEROARYL GROUP; ANGINA, HYPERTENSION, RESPIRATORY DISTRESS, CONGESTIVE HEART FAILURE, RENAL FAILURE, ATHEROSCLEROSIS, INFLAMMATORY DISEASES, STROKES, BRONCHITIS, ASTHMA | ICOS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| EP-1114048-A1 | CARBOLINE DERIVATIVES AS CGMP PHOSPHODIESTERASE INHIBITORS | Bombrun, Agnès (FR) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015639-A1 | CARBOLINE DERIVATIVES AS CGMP PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | KDM4E 3627/4885ALDH1A1 273/4885L3MBTL1 11/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | KDM4E 3627/4885ALDH1A1 273/4885L3MBTL1 11/4885 |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NCOA4, CCDC47, CCDC6 | KDM4E 1095/4885ALDH1A1 2273/4885L3MBTL1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.